about
BAFF, APRIL, TWE-PRIL: Who's who?Regulatory B cells: an exciting target for future therapeutics in transplantationTreatment of primary Sjögren syndrome.High-Grade Salivary-Gland Involvement, Assessed by Histology or Ultrasonography, Is Associated with a Poor Response to a Single Rituximab Course in Primary Sjögren's Syndrome: Data from the TEARS Randomized Trial.Development of the Sjögren's Syndrome Responder Index, a data-driven composite endpoint for assessing treatment efficacy.The role of CD5-expressing B cells in health and disease (review).Level of agreement between 2002 American-European Consensus Group and 2012 American College of Rheumatology classification criteria for Sjögren's syndrome and reasons for discrepanciesAutoantibodies to endothelial cell surface ATP synthase, the endogenous receptor for hsp60, might play a pathogenic role in vasculatides.CD5-positive B cells at the crossroads of B cell malignancy and nonorgan-specific autoimmunity.Recent progress in the understanding of B-cell functions in autoimmunity.Membrane microdomain sphingolipids are required for anti-CD20-induced death of chronic lymphocytic leukemia B cells.Which and How Many Patients Should Be Included in Randomised Controlled Trials to Demonstrate the Efficacy of Biologics in Primary Sjögren's Syndrome?Neurological Disorders in Primary Sjögren's SyndromeDysfunctional B cells in systemic lupus erythematosus.Severe Health-Related Quality of Life Impairment in Active Primary Sjögren's Syndrome and Patient-Reported Outcomes: Data From a Large Therapeutic Trial.B lymphocytes are required for development and treatment of autoimmune diseases.B lymphocytes on the front line of autoimmunity.Endothelium, a target for immune-mediated assault in connective tissue disease.B-cell and T-cell quantification in minor salivary glands in primary Sjögren's syndrome: development and validation of a pixel-based digital procedurePolarization of B effector cells in Sjögren's syndrome.Intravenous immunoglobulin and cytokines: focus on tumor necrosis factor family members BAFF and APRIL.A conspicuous role for B cells In Sjögren's syndrome.Does the BAFF dysregulation play a major role in the pathogenesis of systemic lupus erythematosus?B-cell depletion and repopulation in autoimmune diseases.B lymphocyte cytokines and rheumatic autoimmune disease.Monoclonal anti-CD20 antibodies: mechanisms of action and monitoring of biological effects.B cell-targeted therapies in Sjögren's syndrome.Epigenetics and autoimmunity.Diagnostic accuracy of blood B-cell subset profiling and autoimmunity markers in Sjögren's syndromeThe contribution of epigenetics in Sjögren's Syndrome.Emerging biotherapies for Sjögren's syndrome.Epigenetics in autoimmune disorders: highlights of the 10th Sjögren's syndrome symposium.B-cell tolerance breakdown in Sjögren's syndrome: focus on BAFF.Significance of B cells and B cell clonality in Sjögren's syndrome.The late news on baff in autoimmune diseases.A case for the graft-versus-host disease as a model for B cell-mediated autoimmunity.Disturbance of cytokine networks in Sjögren's syndrome.Are autoimmune diseases predictable?In Sjögren's syndrome, B lymphocytes induce epithelial cells of salivary glands into apoptosis through protein kinase C delta activation.B-lymphocytes govern the pathogenesis of Sjögren's syndrome.
P50
Q21564037-AA9F0468-B20E-41CA-8590-CFC4EC1B8892Q27015093-EF587C85-F840-4598-BF93-BE6D388F24B1Q30249011-EAC47E26-420E-42BD-9CA2-33167427F62CQ30372606-CB122513-3F29-414E-99E3-D98D99ACAD94Q30948155-3D6B673B-DDE1-4A9E-92B5-146A9A469F61Q33535364-607C8BC8-1552-484F-8C02-F95F425CC052Q33765732-F68344E8-F667-4431-9BD9-9DD747010629Q33822283-169CEC6C-AA80-401F-B5EE-93FE7C6F0558Q34018571-B6ECEFAA-6F95-4673-BB36-10688AFF6C2EQ34299834-E44828D3-BB2C-40EF-8A84-955B3E32DB01Q35717890-51EB20F3-35F2-428F-B6B4-D14EAF83AE95Q35774612-A8DE39AC-1227-46E0-A416-99C31DB79B95Q35829655-E420FD9A-2254-407C-81A8-4845B804D269Q35952042-12829FB3-22EA-4898-8042-173151DC77A2Q36070691-C548BA30-6445-4E50-B96B-749B88382019Q36193048-DCE359AE-EA6A-4546-969B-1DDF2129F534Q36399123-3D129D63-9CA8-4EA7-99E5-F0FD50EE1D6CQ36399128-9F55FE17-0184-4924-8516-CB87F52D23ECQ36481706-173C92C2-BE0C-4A88-BA6A-39C32CB50B39Q36888113-2D688D1E-EBF2-427E-AB6D-08447E274131Q36958361-A12E5E75-7FA2-4B3E-A3BF-548460B119F1Q36997265-AF523B1A-034E-4FFA-85A6-3F6E672E0011Q37043955-A8D5C721-1D3A-4FFF-BFF3-027BB5C5B4F3Q37083390-1475A227-3AAB-4FD6-A01E-C40836DB729BQ37535716-B716AB8B-6F3F-4552-8B3A-27FD9EF25274Q37565888-25F98BCA-624C-41B5-888E-9E33CE060535Q37578060-A7932A23-B4CF-43E2-BBF5-B5A4D3EA28F6Q37669513-7B050CF8-91B1-41F0-9FD3-57706E09FF7BQ37689729-BC89861B-C728-4D30-8B5A-1C9A749BCF88Q37695272-F3EEF979-82CB-4F46-A6D5-4D989391DCBFQ37729176-8A2175F0-FAA2-4419-A9D1-65938606CA8EQ37746114-A3AD8640-FE8D-4EC2-9308-B6C900CA79A0Q37748142-721F0BD2-E3A7-4AE4-B4A7-A644078231A3Q37760151-9DF13386-7E47-443C-83B3-B3BEF3BA56A6Q37775299-C18C5E4D-0FAF-4A2C-AB87-6A57C1843F6EQ37801035-EF7DD902-D3C5-4594-8A6D-986E710EE029Q37899957-241455F6-0B81-491D-953C-5E8CFE1F98E5Q37946085-CE1F11B9-101D-4A6C-8293-BE1C71C6DB9CQ37946107-4B7D236B-33A9-4498-91D2-AD39B360CCFFQ37972340-CF45B4B2-9769-474F-A877-4019C25B6BF2
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0001-7287-5541
@en
name
Jacques-Olivier Pers
@ast
Jacques-Olivier Pers
@en
Jacques-Olivier Pers
@es
Jacques-Olivier Pers
@nl
type
label
Jacques-Olivier Pers
@ast
Jacques-Olivier Pers
@en
Jacques-Olivier Pers
@es
Jacques-Olivier Pers
@nl
prefLabel
Jacques-Olivier Pers
@ast
Jacques-Olivier Pers
@en
Jacques-Olivier Pers
@es
Jacques-Olivier Pers
@nl
P214
P106
P1153
6604006201
P214
P31
P496
0000-0001-7287-5541
P7859
viaf-194886884